Ticker >

Fabino Life Sciences share price

Fabino Life Sciences Ltd.

BSE: 543444 SECTOR: Pharmaceuticals & Drugs  12k   3   0

32.25
0 0
BSE: 12 Apr 04:01 PM

Price Summary

Today's High

₹ 32.25

Today's Low

₹ 32.25

52 Week High

₹ 43.84

52 Week Low

₹ 25.5

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

6.77 Cr.

Enterprise Value

6.94 Cr.

No. of Shares

0.21 Cr.

P/E

627.43

P/B

1.65

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  19.59

CASH

0.24 Cr.

DEBT

0.41 Cr.

Promoter Holding

56.82 %

EPS (TTM)

₹  0.05

Sales Growth

-20.01%

ROE

0.26 %

ROCE

0.58%

Profit Growth

-77.04 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-20.01%
3 Year-23.54%
5 YearNA

Profit Growth

1 Year-77.04%
3 Year-46.08%
5 YearNA

ROE%

1 Year0.26%
3 Year1.69%
5 Year3.17%

ROCE %

1 Year0.58%
3 Year2%
5 Year5.56%

Debt/Equity

0.0987

Price to Cash Flow

-10.03

Interest Cover Ratio

1.91355341212698

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2023 56.82 0
Mar 2023 56.82 0
Sep 2022 56.82 0
Mar 2022 56.82 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy liquidity position with current ratio of 10.722610453416.
  • The company has a high promoter holding of 56.82%.

 Limitations

  • The company has shown a poor profit growth of -46.0825328048364% for the Past 3 years.
  • The company has shown a poor revenue growth of -23.5358296362508% for the Past 3 years.
  • Company has a poor ROE of 1.68506353943609% over the past 3 years.
  • Company has a poor ROCE of 1.99502707391129% over the past 3 years
  • Company has high debtor days of 215.290071648231.
  • Company has negative cash flow from operations of -0.6751968.
  • The company is trading at a high PE of 627.43.
  • The company is trading at a high EV/EBITDA of 121.6427.

Quarterly Result (All Figures in Cr.)

Quarterly Data is not available for this company.Report us

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 2.76 7.52 3.06 4.2 3.36
Total Expenditure 2.44 7.2 2.99 4.11 3.33
Operating Profit 0.32 0.32 0.06 0.09 0.03
Other Income 0 0 0 0.01 0.02
Interest 0.29 0.2 0.01 0.01 0.01
Depreciation 0.03 0.02 0.02 0.03 0.03
Exceptional Items 0 0 0 0 0
Profit Before Tax 0 0.1 0.04 0.07 0.01
Tax 0 0.03 0.01 0.02 0
Net Profit 0 0.07 0.03 0.05 0.01
Adjusted EPS (Rs.) 0 4.59 0.25 0.22 0.05

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 0.15 0.15 1.2 2.1 2.1
Total Reserves 0.45 0.52 0.1 2 2.01
Borrowings 0.14 1.08 0.31 0.05 0.41
Other N/C liabilities 0.19 0.14 0.07 0.06 0.03
Current liabilities 7.61 1.68 0.56 0.41 0.45
Total Liabilities 8.54 3.58 2.24 4.62 5
Assets
Net Block 0.1 0.08 0.16 0.17 0.15
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0 0 0 0.04 0.04
Other N/C Assets 0.58 0.58 0.06 0.05 0.04
Current Assets 7.86 2.91 2.02 4.36 4.77
Total Assets 8.54 3.58 2.24 4.62 5
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 0 0.1 0.04 0.07 0.01
Adjustment 0.32 0.22 0.02 0.03 0.04
Changes in Assets & Liabilities -0.13 2.15 -0.48 -2 -0.71
Tax Paid 0 -0.03 -0.03 0 -0.01
Operating Cash Flow 0.18 2.44 -0.45 -1.9 -0.68
Investing Cash Flow -0.01 0 -0.1 -0.05 -0.01
Financing Cash Flow -0.18 -2.37 0.45 2.47 0.34
Net Cash Flow 0 0.07 -0.1 0.52 -0.35

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Sep 2022% Mar 2023% Sep 2023%
promoters 56.82 56.82 56.82 56.82
atul jain 52.38 52.38 52.38 52.38
kamal naini jain 0.13 0.13 0.13 0.13
shanta jain 0.11 0.11 0.11 0.11
shreya jain 0.19 0.19 0.19 0.19
vandana jain 4.00 4.00 4.00 4.00
PARTICULARS Mar 2022% Sep 2022% Mar 2023% Sep 2023%
investors 43.18 43.18 43.18 43.18
akshay kothari - - 1.00 1.00
emrald commercial limited... - 1.57 1.57 1.57
monika malik 1.00 1.00 1.00 1.00
nopea capital services pr... - 4.86 4.86 4.86
pushpa devi 1.14 1.14 1.14 1.14
s k growth fund pvt ltd 2.29 2.29 2.29 2.29
sumit malik 1.00 1.00 1.00 1.00
sumita singh kadian 1.14 1.14 1.14 1.14
varsha chopra - 1.14 1.14 1.14
venkateshwara industrial ... - 3.14 3.00 3.00
aryaman capital markets l... 5.57 - - -
laxmikanth naravi prabhu 1.29 - - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Fabino Life Sciences Stock Price Analysis and Quick Research Report. Is Fabino Life Sciences an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Fabino Life Sciences and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Fabino Life Sciences cash from the operating activity was Rs -0.6751968 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Fabino Life Sciences has a Debt to Equity ratio of 0.0987 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Fabino Life Sciences , the EPS growth was -77.03141283311 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Fabino Life Sciences has OPM of 1.02871643278546 % which is a bad sign for profitability.
     
  • ROE: Fabino Life Sciences have a poor ROE of 0.262817704835051 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Fabino Life Sciences is Rs 32.25. One can use valuation calculators of ticker to know if Fabino Life Sciences share price is undervalued or overvalued.
Last Updated on:
Brief about Fabino Life Sciences
X